Epigenetic Regulation, Nucleosome Dynamics, and Extracellular Histone Neutralization Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C13 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | H4C13 Recombinant Protein Full-length histone H4, >95% purity, Endotoxin <1EU/ug. Sequence Verified. HEK293 or E.coli expression available. |
View H4C13 Products |
| Modified Antigen | H4C13 Acetylation Mimics Site-specific lysine to glutamine substitutions (K5Q, K8Q, K12Q, K16Q) mimicking acetylation states. Theoretical MW verified. |
View H4C13 Products |
| Gene Delivery | H4C13 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. CMV promoter, Puromycin selection. |
View H4C13 Products |
| Benchmark Ab | Anti-H4C13 (Pan-Histone H4) Recombinant rabbit monoclonal, validated for ChIP, WB, and neutralization assays. |
View H4C13 Products |
| Validator | H4C13 siRNA Set Three unique sequences for knockdown verification. >85% mRNA reduction guaranteed. |
View H4C13 Products |
| Nuclear Assembly Partner | H3C11 (Histone H3) Core nucleosome component. Required for octamer assembly assays. |
View H3C11 Products |
| Modification Enzyme | HDAC2 (Histone Deacetylase 2) Primary H4 deacetylase. For functional enzymatic assays. |
View HDAC2 Products |
| Related Target A | HDAC1 (Histone Deacetylase 1) Histone deacetylase interacting with H4 tails. |
View HDAC1 Products |
| Related Target B | BRD4 (BET Family) Epigenetic reader recognizing acetylated histone H4. |
View BRD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nucleosome Assembly Fidelity | Ultra-pure H4C13 (>95% by RP-HPLC) with strict endotoxin control (<1EU/ug) prevents aggregation artifacts in octamer formation |
| Post-Translational Modification Mimicry | Acetylation-mimic mutants (K>Q) precisely engineered for HDAC substrate screening without chemical modification heterogeneity |
| Extracellular Histone Detection | Conformation-stable recombinant protein maintains antigenicity for DAMP (Damage-Associated Molecular Pattern) research |
| Specificity Controls | Pan-Histone H4 antibody validated by siRNA knockdown and peptide competition; modification-specific variants available |
Live H4C13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Epigenetic Therapy Research
- ➤ Extracellular Histone & Sepsis Literature
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding H4C13 diverges into two distinct paradigms: intracellular epigenetic modulation and extracellular damage-associated molecular pattern (DAMP) neutralization. While direct H4C13 targeting remains challenging due to its nuclear localization, the protein serves as a critical biomarker and functional mediator in inflammatory pathologies.
Current R&D focuses on histone deacetylase (HDAC) inhibitors modulating H4C13 acetylation status for oncology applications, particularly in combination with immune checkpoint inhibitors. Simultaneously, a growing therapeutic avenue targets extracellular histones (released during NETosis or necrosis) using neutralizing monoclonal antibodies for sepsis and trauma indications. The next wave of R&D is also shifting toward precise modulators of chromatin structure, such as BET family inhibitors that recognize acetylated H4 tails, and selective reader/writer inhibitors. As precision medicine advances, the demand for site-specific modified H4C13 proteins (acetylated, methylated, citrullinated variants) for mechanism-of-action studies is accelerating.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| HDAC Inhibitors | Celgene (BMS), Novartis, Merck | Oncology (Lymphoma, Myeloma) | Substrate Assay (Need acetylation-mimic H4C13 mutants as HDAC substrates) |
| Neutralizing mAbs | Innovative BioTherapies, Academia | Sepsis, Trauma, Acute Lung Injury | Extracellular Binding Assay (Need conformation-pure H4C13 for ELISA/SPR) |
| Epigenetic Probes | Active Motif, Abcam (Research) | Chromatin Biology | Nucleosome Assembly (Need H4C13+H3C11 tetramer formation validation) |
| PROTACs | Arvinas, C4 Therapeutics | Oncology (Indirect via readers) | Pull-down Assays (Need biotinylated H4C13 peptides/proteins) |
| Biomarker Assays | Roche Diagnostics | Precision Medicine | Standardization (Need Endotoxin-free, consistent proteins) |
Key Mutations and Research Tools
Natural variants of H4C13, such as TEBIVANED1 and TEBIVANED3, result in early developmental defects when expressed in zebrafish (UniProt P62805 VAR_086990, VAR_086991, VAR_086992). These mutations serve as valuable tools for studying histone function and evaluating epigenetic drug responses in disease models.